Reno, NVNCT07805356Now EnrollingIRB Ready

Hypoparathyroidism Clinical Trial in Reno, NV

Access cutting-edge hypoparathyroidism treatment through this phase 3 clinical trial at a research site in Reno. Study-provided care at no cost to qualified participants.

Sponsored by Calcilytix Therapeutics, Inc., a BridgeBio company

Quick Self-Assessment

See if you qualify for this Reno location

Preparing your pre-screening questions…

Expert Care in Reno

Access hypoparathyroidism specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related hypoparathyroidism treatment provided free

Apply for This Reno Location

Check if you qualify for this hypoparathyroidism clinical trial in Reno, NV

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Reno

    Convenient for NV residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Reno site if eligible
  4. 4Begin participation

About This Hypoparathyroidism Study in Reno

The aim of the study is to evaluate the efficacy, safety, and tolerability of orally administered encaleret tablets in participants with chronic hypoparathyroidism (HP).

Sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company

Who Can Participate

Inclusion Criteria

Participants must have had a clinically confirmed diagnosis of chronic HP, with disease duration of at least 26 weeks prior to screening. Cause of chronic HP can be postsurgical, autoimmune or idiopathic.
For participants with nonsurgical chronic HP etiology, sufficient documentation that the participant does not harbor any variants in calcium-sensing receptor (CASR) or GNA11 that are classified as pathogenic, likely pathogenic, or of uncertain significance, with the exception of benign common polymorphisms (CASR A986S and R990G) is needed.
Participants must be on stable doses of calcium and active vitamin D supplementation at or above the following minimum thresholds for at least 6 weeks prior to screening. For participants enrolled in study sites outside Japan:
Calcitriol ≥0.5 micrograms (μg)/day or alfacalcidol ≥1.0 μg/day
Elemental calcium ≥800 milligrams (mg)/day (for example, calcium citrate, calcium carbonate)
Participants must meet the following criteria during screening: cCa within 7.8 to 9.5 mg/deciliter (dL) and 24-hour UCa ≥300 mg/day (males) or ≥250 mg/day (females).
Participants have serum 25-hydroxy (OH) vitamin D concentration of 20 to 80 nanograms (ng)/milliliter (mL) (50-200 nanomoles \[nmol\]/liter \[L\]).
Participants have serum magnesium concentration within the reference range.
Participants on thiazide or loop diuretics must be able to discontinue them during the first 24 weeks of study (treatment).
Participants must be capable of giving signed informed consent or assent, which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol. Key

Exclusion Criteria

Genetically confirmed diagnosis of autosomal dominant hypocalcemia type 1 (ADH1) or autosomal dominant hypocalcemia type 2 (ADH2) due to activating variants in CASR or GNA11, respectively.
History of hypocalcemic seizure in the 3 months prior to screening.
History of cancer (except non-melanoma skin cancer) or bone metastases in the 5 years prior to screening.
Prior skeletal irradiation, chemotherapy with alkylating agents, or diagnosis of Paget's disease, fibrous dysplasia, chronic osteomyelitis, bone infarcts, benign bone tumors with curettage and grafting, retinoblastoma, or Li-Fraumeni syndrome.
Presence or history of any disease or condition (for example, drug or alcohol dependence) that, in the view of the investigator, would affect the participant's safety or places the participant at high risk of poor treatment compliance or of not completing the study. Other protocol-defined inclusion/exclusion criteria apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Reno?

Yes, this clinical trial (NCT07805356) has an active research site in Reno, NV that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Hypoparathyroidism Treatment Options in Reno, NV

If you're searching for hypoparathyroidism treatment options in Reno, NV, this clinical trial (NCT07805356) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Reno research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced hypoparathyroidism specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hypoparathyroidism clinical trials near you to find additional studies recruiting in your area.

More Rheumatoid Arthritis Trials in Reno, NV

See all rheumatoid arthritis clinical trials recruiting in Reno — not just this study.

Browse Rheumatoid Arthritis Trials in Reno →

Browse More Trials by Condition

Rheumatoid Arthritis TrialsOsteogenesis Imperfecta TrialsAll Conditions →

Ready to Join in Reno?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Reno, NV